RXRX CFO sells 7,956 shares in planned trade

Recursion Pharmaceuticals Chief Financial Officer Ben R. Taylor reported routine share movements in company stock.

Rhea-AI Filing Summary

Recursion Pharmaceuticals Chief Financial Officer Ben R. Taylor reported routine share movements in company stock. On March 17, 2026, he completed an open-market sale of 7,956 shares of Class A Common Stock at $3.39 per share. On March 16, 2026, 7,075 shares were disposed to cover tax obligations tied to net settlement of restricted stock units, which is not an open-market trade. After these transactions, Taylor directly held 1,180,318 shares of Class A Common Stock. The open-market sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 30, 2025, indicating the timing was planned in advance.

Insider Trade Summary 10b5-1

Net Seller: 7,956 shares

Net Sell 2 txns

Insider Taylor Ben R

Role Chief Financial Officer

Sold 7,956 shs ($27K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	7,956	$3.39	$27K
Exercise Price or Tax Liability	Class A Common Stock	7,075	$3.42	$24K

Holdings After Transaction: Class A Common Stock — 1,180,318 shares (Direct)

Footnotes (2)

1. F1. Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
2. F2. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did RXRX CFO Ben Taylor report?

Ben Taylor reported an open-market sale of 7,956 Class A shares at $3.39 and a separate 7,075-share tax-withholding disposition tied to restricted stock units. These transactions adjusted his holdings but left him with over 1.18 million directly owned shares.

How many Recursion Pharmaceuticals (RXRX) shares does the CFO hold after these trades?

After the reported transactions, CFO Ben Taylor directly holds 1,180,318 shares of Recursion Pharmaceuticals Class A Common Stock. This figure reflects both the 7,956-share open-market sale and the 7,075-share tax-withholding disposition disclosed in the Form 4 filing.

Was the RXRX CFO’s stock sale made under a Rule 10b5-1 plan?

Yes. The open-market sale of 7,956 Class A shares by CFO Ben Taylor was executed under a Rule 10b5-1 trading plan adopted on September 30, 2025, indicating the trade’s timing was pre-scheduled rather than discretionary.

What was the price of the RXRX CFO’s recent share sale?

CFO Ben Taylor sold 7,956 shares of Recursion Pharmaceuticals Class A Common Stock at a price of $3.39 per share. This was an open-market transaction disclosed in the Form 4, separate from the tax-withholding share disposition.

Is the 7,075-share RXRX transaction a sale by the CFO?

The 7,075-share transaction is a tax-withholding disposition, not an open-market sale. These shares were withheld by the company to satisfy tax obligations related to net settlement of restricted stock units previously granted to CFO Ben Taylor.

What is the net effect of the RXRX CFO’s recent transactions on his holdings?

The Form 4 shows a 7,956-share open-market sale and 7,075 shares withheld for taxes, leaving CFO Ben Taylor with 1,180,318 shares. The transactions modestly reduce his stake while largely reflecting routine compensation and pre-planned trading activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 05:52 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Taylor Ben R

(Last) (First) (Middle)

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY UTAH 84101

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	03/16/2026		F(1)		7,075	D	$3.42	1,188,274	D
Class A Common Stock	03/17/2026		S(2)		7,956	D	$3.39	1,180,318	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.

2. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025.

Remarks:

	/s/Jonathan Golightly, attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)